NASDAQ · ANL
Adlai Nortye Ltd.
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
Loading market information…
OTC · ADAPY · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Adaptimmune Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 92.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Adaptimmune Therapeutics plc’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Adaptimmune Therapeutics plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Aug 12, 2024 | $0.24+442.86% vs estimate | $128.23M+216.85% vs estimate |
|---|
| Q1 2024 | May 15, 2024 | -$0.18-80.0% vs estimate | $5.68M-42.53% vs estimate |
|---|
| Q4 2023 | Mar 6, 2024 | -$0.24-100.0% vs estimate | $231.00K-99.11% vs estimate |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
$3.54+$0.22 (+6.63%)
Tharimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.01% below the high.
$20.80+$0.83 (+4.16%)
Apollomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.48% below the high.
$1.52+$0.01 (+0.66%)
Lipocine Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.71% below the high.
₪0.01₪0.00 (0.0%)
BioLineRx Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.62% below the high.
$8.72-$0.03 (-0.29%)
Moleculin Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.23% below the high.
$0.12$0.00 (0.0%)
OSR Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.17% below the high.
$2.11+$0.13 (+6.57%)
Ernexa Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.6% below the high.
